The Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2011 Apr 26

PMID 21514249

Citations 4410

Authors

Marilyn S Albert

Steven T DeKosky

Dennis Dickson

Bruno Dubois

Howard H Feldman

Nick C Fox

Anthony Gamst

David M Holtzman

William J Jagust

Ronald C Petersen

Peter J Snyder

Maria C Carrillo

Bill Thies

Creighton H Phelps

Affiliations

Soon will be listed here.

Abstract

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.

Citing Articles

Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer's disease.

Ketron G, Grun F, Grill J, Feldman H, Rissman R, Brewer G Alzheimers Res Ther. 2025; 17(1):59.

PMID: 40069789 PMC: 11895359. DOI: 10.1186/s13195-025-01693-y.

A novel method for objective quantification of apathy based on gaze and physiological reactivity to stimuli presented in a virtual reality environment.

Ravona-Springer R, Koren O, Galor N, Lapid M, Bahat Y, Fluss R Alzheimers Dement (Amst). 2025; 17(1):e70020.

PMID: 40061180 PMC: 11886987. DOI: 10.1002/dad2.70020.

Amyloid pathology related to aberrant structure-function coupling of brain networks in Alzheimer's disease: insights from [F]-florbetapir PET imaging.

Chen H, Zhang M, Wei M, Yu X, Wang Y, Yang J Eur J Nucl Med Mol Imaging. 2025; .

PMID: 40053120 DOI: 10.1007/s00259-025-07172-8.

Comparison of plasma p-tau217 and p-tau181 in predicting amyloid positivity and prognosis among Korean memory clinic patients.

Kwon H, Hwang M, Koh S, Choi S, Lee J, Kim H Sci Rep. 2025; 15(1):7791.

PMID: 40044785 PMC: 11882798. DOI: 10.1038/s41598-025-90232-8.

Physical Activity, Alzheimer Plasma Biomarkers, and Cognition.

Kim S, Shin D, Ham H, Kim Y, Gu Y, Kim H JAMA Netw Open. 2025; 8(3):e250096.

PMID: 40042844 PMC: 11883494. DOI: 10.1001/jamanetworkopen.2025.0096.

References

Bennett D, Schneider J, Bienias J, Evans D, Wilson R . Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005; 64(5):834-41. DOI: 10.1212/01.WNL.0000152982.47274.9E. View

Petersen R . Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256(3):183-94. DOI: 10.1111/j.1365-2796.2004.01388.x. View

Dubois B, Feldman H, Jacova C, DeKosky S, Barberger-Gateau P, Cummings J . Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6(8):734-46. DOI: 10.1016/S1474-4422(07)70178-3. View

Shaw L, Vanderstichele H, Knapik-Czajka M, Clark C, Aisen P, Petersen R . Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009; 65(4):403-13. PMC: 2696350. DOI: 10.1002/ana.21610. View

Bertram L, Lill C, Tanzi R . The genetics of Alzheimer disease: back to the future. Neuron. 2010; 68(2):270-81. DOI: 10.1016/j.neuron.2010.10.013. View

Petersen R, Parisi J, Dickson D, Johnson K, Knopman D, Boeve B . Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006; 63(5):665-72. DOI: 10.1001/archneur.63.5.665. View

Selkoe D . Defining molecular targets to prevent Alzheimer disease. Arch Neurol. 2005; 62(2):192-5. DOI: 10.1001/archneur.62.2.192. View

Sperling R, Aisen P, Beckett L, Bennett D, Craft S, Fagan A . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):280-92. PMC: 3220946. DOI: 10.1016/j.jalz.2011.03.003. View

Jagust W . Positron emission tomography and magnetic resonance imaging in the diagnosis and prediction of dementia. Alzheimers Dement. 2009; 2(1):36-42. DOI: 10.1016/j.jalz.2005.11.002. View

10.

Blennow K, Hampel H . CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003; 2(10):605-13. DOI: 10.1016/s1474-4422(03)00530-1. View

11.

Fagan A, Mintun M, Mach R, Lee S, Dence C, Shah A . Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2005; 59(3):512-9. DOI: 10.1002/ana.20730. View

12.

Jack Jr C, Lowe V, Senjem M, Weigand S, Kemp B, Shiung M . 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008; 131(Pt 3):665-80. PMC: 2730157. DOI: 10.1093/brain/awm336. View

13.

Petersen R, Smith G, Waring S, Ivnik R, Tangalos E, Kokmen E . Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56(3):303-8. DOI: 10.1001/archneur.56.3.303. View

14.

Jack Jr C, Albert M, Knopman D, McKhann G, Sperling R, Carrillo M . Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):257-62. PMC: 3096735. DOI: 10.1016/j.jalz.2011.03.004. View

15.

Schellenberg G . Early Alzheimer's disease genetics. J Alzheimers Dis. 2006; 9(3 Suppl):367-72. DOI: 10.3233/jad-2006-9s341. View

16.

Kantarci K, Jack Jr C . Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am. 2003; 13(2):197-209. DOI: 10.1016/s1052-5149(03)00025-x. View

17.

Hampel H, Frank R, Broich K, Teipel S, Katz R, Hardy J . Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010; 9(7):560-74. DOI: 10.1038/nrd3115. View

18.

Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund L . Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004; 256(3):240-6. DOI: 10.1111/j.1365-2796.2004.01380.x. View

19.

Lyketsos C, Colenda C, Beck C, Blank K, Doraiswamy M, Kalunian D . Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry. 2006; 14(7):561-72. DOI: 10.1097/01.JGP.0000221334.65330.55. View

20.

Markesbery W, Schmitt F, Kryscio R, Davis D, Smith C, Wekstein D . Neuropathologic substrate of mild cognitive impairment. Arch Neurol. 2006; 63(1):38-46. DOI: 10.1001/archneur.63.1.38. View